Gary J Kelloff

Gary J Kelloff

UNVERIFIED PROFILE

Are you Gary J Kelloff?   Register this Author

Register author
Gary J Kelloff

Gary J Kelloff

Publications by authors named "Gary J Kelloff"

Are you Gary J Kelloff?   Register this Author

37Publications

862Reads

42Profile Views

Biomarker development in the context of urologic cancers.

Urol Oncol 2015 Jun 5;33(6):295-301. Epub 2015 Mar 5.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521394PMC
June 2015

Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.

J Radiol Prot 2014 Jun 14;34(2):R25-52. Epub 2014 Apr 14.

Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/0952-4746/34/2/R25DOI Listing
June 2014

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Clin Cancer Res 2014 Mar;20(6):1428-44

Authors' Affiliations: New Enterprise Associates, Inc., Menlo Park; CCS Associates, Mountain View; Myraqa, Redwood Shores, California; Johnson & Johnson/Veridex, LLC, Raritan, New Jersey; University of Texas, MD Anderson Cancer Center, Houston, Texas; Center for Diagnostics and Radiologic Health, Office of In Vitro Diagnostics, Personalized Medicine Program, Silver Spring; Center for Medical Technology Policy, Baltimore; Opus Three LLC; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, Maryland; and Kaiser Permanente Research Affiliates Evidence-Based Practice Center, Kaiser Permanente Center for Health Research, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2961DOI Listing
March 2014

Cancer biomarkers: selecting the right drug for the right patient.

Nat Rev Drug Discov 2012 Feb 10;11(3):201-14. Epub 2012 Feb 10.

National Cancer Institute, Cancer Imaging Program, EPN Rm 6058, 6130 Executive Blvd, Bethesda, Maryland 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3651DOI Listing
February 2012

Challenges in clinical prostate cancer: role of imaging.

AJR Am J Roentgenol 2009 Jun;192(6):1455-70

Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.09.2579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893141PMC
June 2009

Early detection of oral neoplasia: watching with new eyes.

Cancer Prev Res (Phila) 2009 May 28;2(5):405-8. Epub 2009 Apr 28.

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, 6130 Executive Boulevard, Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0064DOI Listing
May 2009

Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.

Drug Discov Today 2008 Sep 24;13(17-18):748-59. Epub 2008 Jul 24.

Molecular Tracer LLC, Bethesda, MD 20814, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2008.05.009DOI Listing
September 2008

Regulatory and reimbursement challenges for molecular imaging.

Radiology 2007 Dec;245(3):645-60

Department of Radiology, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2121, Salt Lake City, UT 84112-5550, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2453060737DOI Listing
December 2007

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.

Nat Rev Cancer 2007 Jul;7(7):508-18

National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Executive Plaza North Room 6058, 6130 Executive Boulevard, Rockville, Maryland 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2154DOI Listing
July 2007

Imaging and oncologic drug development.

J Clin Oncol 2006 Jul;24(20):3261-73

Department of Medicine (Hematology/Oncology), the Abramson Comprehensive Cancer Center, and the Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.5623DOI Listing
July 2006

Development of cancer chemopreventive drugs based on mechanistic approaches.

Mutat Res 2005 Dec 3;591(1-2):16-23. Epub 2005 Aug 3.

National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892-7322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mrfmmm.2005.04.018DOI Listing
December 2005

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.

Carcinogenesis 2005 May 3;26(5):1000-7. Epub 2005 Feb 3.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgi038DOI Listing
May 2005

New science-based endpoints to accelerate oncology drug development.

Eur J Cancer 2005 Mar 22;41(4):491-501. Epub 2005 Jan 22.

Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Cancer Institute, Executive Plaza North Room 6038, 9000 Rockville Pike, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2004.12.006DOI Listing
March 2005

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res 2004 Jun;10(11):3885-96

University of California, San Francisco Cancer Center, San Francisco, California 94115-1710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0785DOI Listing
June 2004

Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.

Clin Cancer Res 2004 Jun;10(11):3908-18

Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0789DOI Listing
June 2004

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

Clin Cancer Res 2004 Jun;10(11):3927-33

Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0788DOI Listing
June 2004

Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

Clin Cancer Res 2003 Oct;9(12):4606-13

Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
October 2003

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

Cancer Epidemiol Biomarkers Prev 2003 Jul;12(7):593-6

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
July 2003

9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats.

Cancer Res 2002 Sep;62(18):5178-82

Department of Surgical Oncology, College of Medicine, University of Illinois, 840 South Wood Street MC 820, Chicago, IL 60612, USA.

View Article

Download full-text PDF

Source
September 2002